Neurocrine Biosciences Inc (NBIX) Share-based Compensation (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Share-based Compensation for 17 consecutive years, with $57.2 million the latest figure, recorded in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $57.2 million, up 8.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $222.3 million (up 9.08% YoY), and the FY2025 annual result was $217.9 million, up 11.46% from the prior year.
• Share-based Compensation was $57.2 million for Q1 2026 at Neurocrine Biosciences, down from $58.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $68.5 million in Q2 2023 and troughed at $37.0 million in Q1 2022.
• Average Share-based Compensation over 5 years is $49.3 million, with a median of $47.8 million recorded in 2023.
• The widest YoY moves for Share-based Compensation: up 74.28% in 2024, down 37.08% in 2024.
• Over 5 years, Share-based Compensation stood at $43.5 million in 2022, then decreased by 12.41% to $38.1 million in 2023, then soared by 74.28% to $66.4 million in 2024, then declined by 11.75% to $58.6 million in 2025, then slipped by 2.39% to $57.2 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $57.2 million in Q1 2026, $58.6 million in Q4 2025, and $53.7 million in Q3 2025.